TrialInvestigational new drugs2016

Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer.

Joseph Kattan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.